Company: HCTI
Filing Date: 2025-11-28
Form Type: S-3
Source: 0001213900-25-115888
Chunk: 28

Company: Healthcare Triangle, Inc.
Filing Date: 2025-11-28
Form: S-3
Chunk 28
---
any proceeds from the sale of shares of Common Stock that may be sold from time to time pursuant to this prospectus; however, we will
receive proceeds from the cash exercise of the Common Warrants. We currently intend to use these net proceeds for general corporate purposes,
which may include working capital, and general capital expenditures. We have not determined the amount of net proceeds to be used specifically
for any of such purposes.

The expected use of net proceeds from the cash
exercise of the Common Warrants represents our intentions based upon our current plans and business conditions, which could change in
the future as our plans and business conditions evolve and change. The amounts and timing of our actual expenditures, specifically with
respect to working capital, may vary significantly depending on numerous factors. As a result, our management will retain broad discretion
over the allocation of the net proceeds from this offering.

We will bear the out-of-pocket costs, expenses
and fees incurred in connection with the registration of shares of our Common Stock to be sold by the Selling Stockholders pursuant to
this prospectus. Other than registration expenses, the Selling Stockholders will bear any underwriting discounts, commissions, placement
agent fees or other similar expenses payable with respect to sales of shares of our Common Stock.

<div align='center'>14

SELLING STOCKHOLDERS</div>

The Conversion Shares are being offered by the
Selling Stockholders. For additional information regarding the issuances of Conversion Shares, see “Notes Private Placement”
above. We are registering the Conversion Shares in order to permit the Selling Stockholders to offer the shares of Common Stock for resale
from time to time.

The table below lists the Selling Stockholders
and provides information regarding their beneficial ownership of shares of Common Stock by each of the Selling Stockholders. The second
column lists the number of shares of Common Stock beneficially owned by the Selling Stockholders, based on their ownership of the shares
of Common Stock and shares of Common Stock issuable upon conversion of the Notes, assuming conversion of the Notes held by the Selling
Stockholders, without regard to any limitations on exercises. The third column lists the maximum number of shares of Common Stock being
offered by this prospectus by the Selling Stockholders, also without regard to any limitations on exercises.

In accordance with the terms of the Registration
Rights Agreement, this prospectus generally covers the resale of the maximum number of shares of Common Stock issuable upon full conversion
of $15,000,000 of Notes at $0.38 per